ERBB2 and neoplasm: Consistent with previous reports on other tumor-targeting IgE antibodies,15 16 20 anti-HER2 IgE cross-linking, also stimulated upregulation of CCL2, and of the anti-inflammatory mediator IL-10 (figure 4C).